Leach et al. Supplemental Figure 1



Supplemental Figure 1. *TMPRSS2* expression is reduced by antiandrogens. LNCaP and A549 were incubated in full media for 48 or 72 h + 10 nM mibolerone ± 10 µM enzalutamide (ENZA). RNA was harvested, reverse transcribed and qPCR performed to quantify the expression of *TMPRSS2*. Mean of 3 independent repeats (± 1SEM). Two-way ANOVA with Sidak's multiple comparison test. LNCaP 48 h p=1.1x10⁻⁸, 72 h p=4.3x10⁻⁹; A549 48 h p=6.4x10⁻⁵, 72 h p=2.0x10^{-5.} A549 and LNCaP cells were lysed and proteins separated using SDS-PAGE. Immunoblotting was performed to visualise AR expression levels and a-tubulin was used as a loading control. Source data are provided as a Source Data file.

Leach et al. Supplemental Figure 2

10X magnification

20X magnification



Supplemental Figure 2. Enzalutamide downregulates Ar expression in the mouse lung. Pten^{loxp/loxp};Pb-Cre4 mice were treated with 50 mg/kg enzalutamide (ENZA, n=9) or vehicle control (VC, n=8) once daily for 3 days. Lungs were harvested, formalin fixed and wax embedded. Immunohistochemistry was performed using an antibody specific for the Ar. Representative immunostaining of epithelial cells (*) and parenchyma/AT cells (#). Bar = 50 μ m.

Leach et al. Supplemental Figure 3



Supplemental Figure 3. Enzalutamide reduces TMPRSS2 expression and SARS-CoV-2 cell entry. A549 were grown in full media \pm 10 μ M enzalutamide (ENZA) for 72 hrs. a) RNA was harvested and qPCR performed to quantify *TMPRSS2* expression in response to vehicle control (VC) or ENZA. One-tailed t-test p=0.0197 b) Cells were lysed and proteins separated using SDS-PAGE. TMPRSS2 levels were visualized using immunoblotting (representative image, n=3). Densitometry was performed and TMPRSS2 expression normalised to α -tubulin levels. c) Cells were transduced with SARS-CoV-2 Spike protein lentiviral particles expressing luciferase. Cells were left for an additional 48 h and luciferase assays performed. Luciferase data were normalised to total protein content. Mean of 3 independent repeats \pm 1SE. One-tailed t-test, p=0.0072. Source data are provided as a Source Data file.

Leach et al. Supplemental Table 1

Supplemental Table 1. Table of the chromatin areas associated with the MA0007.2 AR motif. Tabled are the 17 highest scoring motif matches in the both regulatory regions indicated in Figure 6. First column is the identifier attributed to each motif site, followed by the motif name, the chromosomal region of the motif match, statistical measures of how exact a match there is between the DNA region and the motif, and the matched sequence indicates the DNA sequence the motif matches. The p-value (two-sided) was taken from log-likelihood ratio score and assumes a zero-order null model. This value represents the probability of a random part of the motif scoring similarly to the observed match. The q-value was calculated using a Benjamini & Hochberg modification of the P-value.

Regulatory region 1 Chr21:41490000-41580500

			Start	End	Strand	p-value	q-value	Matched Sequence
RG1a	MA0007.2	Chr21	41498078	41498092	-	0.0000367	0.359	AAGAACTGTAAGTAC
RG1b	MA0007.2	Chr21	41521454	41521468	+	0.0000198	0.359	GGGCACAGCCTGAGC
RG1c	MA0007.2	Chr21	41521553	41521567	-	0.0000737	0.392	CAGAACAGCCTGTGG
RG1d	MA0007.2	Chr21	41528878	41528892	-	0.0000652	0.392	CAGAACATTATGGAC
RG1e	MA0007.2	Chr21	41529170	41529184	-	0.0000354	0.359	GGGCACACGCTGTTA
RG1f	MA0007.2	Chr21	41532582	41532596	+	0.0000215	0.359	GAGAACAGTGGGTTC
RG1g	MA0007.2	Chr21	41569350	41569364	-	0.000068	0.392	AGGAACACCGGGAGC
RG1h	MA0007.2	Chr21	41578975	41578989	+	9.64E-07	0.171	GAGAACATCGTGTGC
RG1i	MA0007.2	Chr21	41578977	41578991	-	3.27E-06	0.29	AGGCACACGATGTTC

Regulatory region 2 Chr21:4160000-41690500

			Start	End	Strand	p-value	q-value	Matched Sequence
RG2a	MA0007.2	Chr21	41605770	41605784	-	0.0000931	0.514	AGGTACAAAATGAAA
RG2b	MA0007.2	Chr21	41611959	41611973	-	0.0000994	0.514	AGGTACACACTGATG
RG2c	MA0007.2	Chr21	41630148	41630162	-	4.91E-06	0.263	AAGTACAGAGTGCGC
RG2d	MA0007.2	Chr21	41642129	41642143	-	0.0000122	0.269	GGGAACAGGCAGTGT
RG2e	MA0007.2	Chr21	41656029	41656043	-	0.0000922	0.514	AGGTACAAAGGGTAC
RG2f	MA0007.2	Chr21	41676130	41676144	+	0.000068	0.498	AAGAACACTGTGAGG
RG2g	MA0007.2	Chr21	41683746	41683760	+	0.0000209	0.367	GGGAACAGAAAGGGC
RG2h	MA0007.2	Chr21	41687334	41687348	+	0.0000314	0.367	CAGCACAGAGTGAAC

Leach et al. Supplemental Table 2

Supplemental Table 2. Primer sequences used in the study

Human qPCR Primers TMPRSS2 FKBP5 L19 GAPDH	Forward (5'-3') CCTGTGTGCCAAGACGACTG ATTATCCGGAGAACCAAACG GCGGAAGGGTACAGCCAAT ATGGGGAAGGTGAAGGTCG	Reverse (5'-3') TTATAGCCCATGTCCCTGCAG CAAACATCCTTCCACCACAG GCAGCCGGCGCAAA GGGGTCATTGATGGCAACAATA
Mouse qPCR Primers	Forward (5'-3')	Reverse (5'-3')
Tmprss2	GAGAACCGTTGTGTTCGTCTC	GCTCTGGTCTGGTATCCCTTG
Ace2	TGATGAATCAGGGCTGGGATG	ATTCTGAAGTCTCCGTGTCCC
Ar	TGGGACCTTGGATGGAGAAC	CTCCGTAGTGACAGCCAGAAL19
L19	GAAATCGCCAATGCCAAC	TCTTAGACCTGCGAGCCTCA
Gapdh	GCAAAGTGGAGATTGTTGCCAT	CCTTGACTGTGCCGTTGAATTT
eta-actin	CCTCTATGCCAACACAGTGC	CCTGCTTGCTGATCCACATC
ChIP-qPCR Primers	Forward (5'-3')	Reverse (5'-3')
ChIP-qPCR Primers RG1a	Forward (5'-3') CCTTGCAATTGCTGACCCCA	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT
ChIP-qPCR Primers RG1a RG1d	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC
ChIP-qPCR Primers RG1a RG1d RG1e	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC CTGCTGTGTTACAAACGACG	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC
ChIP-qPCR Primers RG1a RG1d RG1e RG1f	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC CTGCTGTGTTACAAACGACG TTACACCACTGGCTATTGGCTC	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC CTTTTCAGCCTTGGACATCGG
ChIP-qPCR Primers RG1a RG1d RG1e RG1f RG1g	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC CTGCTGTGTTACAAACGACG TTACACCACTGGCTATTGGCTC GGCTATTGGCTCCTTCTTCTT	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC CTTTTCAGCCTTGGACATCGG CCTGTTTCTAAACCTTTTCAGCCT
ChIP-qPCR Primers RG1a RG1d RG1e RG1f RG1g RG1h	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC CTGCTGTGTTACAAACGACG TTACACCACTGGCTATTGGCTC GGCTATTGGCTCCTTCTTCTT CCAAAAGTGTTGCTCCGGCTT	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC CTTTTCAGCCTTGGACATCGG CCTGTTTCTAAACCTTTTCAGCCT AGAAGTGCAGCTGGCATCG
ChIP-qPCR Primers RG1a RG1d RG1e RG1f RG1g RG1h RG2a	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC CTGCTGTGTTACAAACGACG TTACACCACTGGCTATTGGCTC GGCTATTGGCTCCTTCTTTT CCAAAAGTGTTGCTCGGCTT GCAACCTGAGCCTGTTGACT	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC CTTTTCAGCCTTGGACATCGG CCTGTTTCTAAACCTTTTCAGCCT AGAAGTGCAGCTGGCATCG CTCAGGTCAGG
ChIP-qPCR Primers RG1a RG1d RG1e RG1f RG1g RG1h RG2a RG2b	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC CTGCTGTGTTACAAACGACG TTACACCACTGGCTATTGGCTC GGCTATTGGCTCCTTCTTTT CCAAAAGTGTTGCTCGGCTT GCAACCTGAGCCTGTTGACT TCACATCTGGAGGCACTCTG	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC CTTTTCAGCCTTGGACATCGG CCTGTTTCTAAACCTTTTCAGCCT AGAAGTGCAGCTGGCATCG CTCAGGTCAGG
ChIP-qPCR Primers RG1a RG1d RG1e RG1f RG1g RG1h RG2a RG2b RG2d	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC CTGCTGTGTTACAAACGACG TTACACCACTGGCTATTGGCTC GGCTATTGGCTCCTTCTTTTT CCAAAAGTGTTGCTCGGCTT GCAACCTGAGCCTGTTGACT TCACATCTGGAGGCACTCTG ACAGAACGGAAAGGAAGGCA	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC CTTTTCAGCCTTGGACATCGG CCTGTTTCTAAACCTTTTCAGCCT AGAAGTGCAGCTGGCATCG CTCAGGTCAGG
ChIP-qPCR Primers RG1a RG1d RG1e RG1f RG1g RG1h RG2a RG2b RG2b RG2d	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC CTGCTGTGTTACAAACGACG TTACACCACTGGCTATTGGCTC GGCTATTGGCTCCTTCTTTT CCAAAAGTGTTGCTCGGCTT GCAACCTGAGCCTGTTGACT TCACATCTGGAGGCACTCTG ACAGAACGGAAAGGAAGGCA AGTTACAACCACTGGGTGGG	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC CTTTTCAGCCTTGGACATCGG CCTGTTTCTAAACCTTTTCAGCCT AGAAGTGCAGCTGGCATCG CTCAGGTCAGG
ChIP-qPCR Primers RG1a RG1d RG1e RG1f RG1g RG1h RG2a RG2b RG2b RG2d RG2c RG2e	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGAGTGC CTGCTGTGTTACAAACGACG TTACACCACTGGCTATTGGCTC GGCTATTGGCTCCTTCTTTT CCAAAAGTGTTGCTCGGCTT GCAACCTGAGCCTGTTGACT TCACATCTGGAGGCACTCTG ACAGAACGGAAAGGAAGGCA AGTTACAACCACTGGGTGGG ACACCCCTAGAGTATTTTCCCC	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC CTTTTCAGCCTTGGACATCGG CCTGTTTCTAAACCTTTTCAGCCT AGAAGTGCAGCTGGCATCG CTCAGGTCAGG
ChIP-qPCR Primers RG1a RG1d RG1e RG1f RG1g RG1h RG2a RG2b RG2b RG2d RG2c RG2c RG2f	Forward (5'-3') CCTTGCAATTGCTGACCCCA CATGAGGGCAGTGAGAGTGC CTGCTGTGTTACAAACGACG TTACACCACTGGCTATTGGCTC GGCTATTGGCTCCTTCTTTTCTT	Reverse (5'-3') ACAGCAAGATGGCTTTGAACT TTTCTCTGGTCCCAGCCATC CTCCCCGCTCTAGGATGTC CTTTTCAGCCTTGGACATCGG CCTGTTTCTAAACCTTTTCAGCCT AGAAGTGCAGCTGGCATCG CTCAGGTCAGG